RINVOQ™ arthritis treatment granted approval by FDA
The FDA has given its approval to RINVOQ for the treatment of active rheumatoid arthritis after the drug reached its endpoints in clinical trials.
List view / Grid view
The FDA has given its approval to RINVOQ for the treatment of active rheumatoid arthritis after the drug reached its endpoints in clinical trials.
Sanofi has won the latest appeal for the patent of its top oncology product, Jevtana (cabazitaxel).
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
Pfizer has volountarily recalled the migraine medication Relpax because of the potential presence of Pseudomonas and Burkholderia.
A leaked government dossier has stated that in the event of a no-deal Brexit, the UK will face severe medicinal shortages.
SGS Life Sciences launches OneVision, a global digitalisation initiative to create a single, integrated network of testing laboratories.
An MHRA consultation is due to end on 31 August, with public comments on AQbD principles closing soon.
The cancer therapeutic, Rozlytrek, has gained FDA approval as well as Priority Review, Breakthrough Therapy and Orphan Drug Designations.
Researchers have developed silica spheres to contain cancer therapeutics that melt at certain temperatures and have the potential to improve drug delivery.
A complete response letter (CRL) has been sent to Dr Reddy’s for two generic products.
The DHSC has confirmed that several pharmaceutical industry bodies have agreed to NDAs regarding plans for a no-deal Brexit.
The CMA alleges that Aspen broke competition law, prompting the drug supplier to offer a payment and other compensations to the NHS.
Pretomanid in combination with bedaquiline and linezolid has been approved by the FDA for treatment-resistant tuberculosis of the lungs.
A first-of-its-kind experimental chlamydia vaccine trial has been found to be safe and able to provoke an immune response.
The European Commission has approved the drug for two indications: chronic lymphocytic leukaemia and Waldenström's macroglobulinemia.